Skip to main content
KISSEI PHARMACEUTICAL CO.,LTD. logo

KISSEI PHARMACEUTICAL CO.,LTD. — Investor Relations & Filings

Ticker · 4547 ISIN · JP3240600001 T Manufacturing
Open in API
Filings indexed 82 across all filing types
Latest filing 2020-11-13 Interim / Quarterly Rep…
Country JP Japan
Listing T 4547

About KISSEI PHARMACEUTICAL CO.,LTD.

https://www.kissei.co.jp/e_contents/

Kissei Pharmaceutical Co., Ltd. is a research-driven company engaged in the discovery, development, manufacturing, and sale of pharmaceutical products. The company concentrates its research and development investments in key therapeutic areas, including urology, renal diseases and dialysis, and rare or intractable diseases. Its broader product portfolio also addresses conditions in metabolic and endocrinological, obstetrics and gynecological, and ophthalmic fields. Committed to creating innovative medicines, Kissei aims to contribute to global health by addressing unmet medical needs. The company also operates in the health foods sector.

Recent filings

Filing Released Lang Actions
四半期報告書－第76期第2四半期(令和2年7月1日－令和2年9月30日)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed with the Kanto Local Finance Bureau in Japan, as indicated by the header and the regulatory reference (Financial Instruments and Exchange Act). It contains detailed financial statements, including the balance sheet, income statement, and cash flow analysis for the second quarter of the 76th fiscal period. It is a comprehensive financial report, not an announcement or a summary, and therefore qualifies as an Interim/Quarterly Report (IR). Q2 2020
2020-11-13 Japanese
変更報告書
Major Shareholding Notification Classification · 100% confidence The document is a 'Change Report' (変更報告書) filed under the Japanese Financial Instruments and Exchange Act (Article 27-25, Paragraph 1), specifically titled 'Large Volume Holding Report' (大量保有報告書). This is a regulatory filing used to disclose changes in share ownership exceeding 5% of a company's total outstanding shares. In the provided taxonomy, this falls under 'Major Shareholding Notification'.
2020-08-11 Japanese
四半期報告書－第76期第1四半期(令和2年4月1日－令和2年6月30日)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed under the Financial Instruments and Exchange Act of Japan. It contains detailed financial statements, including the balance sheet and management analysis for the first quarter of the 76th fiscal period (April 1, 2020, to June 30, 2020). As it provides comprehensive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. Q1 2021
2020-08-11 Japanese
有価証券報告書－第75期(平成31年4月1日－令和2年3月31日)
Annual Report Classification · 100% confidence The document is a Japanese 'Yuuka Shouken Houkokusho' (Securities Report), which is the Japanese equivalent of a 10-K annual report. It contains the header information for the 75th fiscal year (2019-04-01 to 2020-03-31) and includes XBRL-like tagging for financial statements, segment reporting, and shareholder information, confirming it is the full annual report rather than an announcement. FY 2020
2020-06-26 Japanese
四半期報告書－第75期第3四半期(令和1年10月1日－令和1年12月31日)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed with the Kanto Local Finance Bureau in Japan, as indicated by the header and the legal basis (Financial Instruments and Exchange Act). It contains detailed financial statements, including the balance sheet and management analysis for the third quarter of the 75th fiscal period (ending December 31, 2019). It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2020
2020-02-13 Japanese
四半期報告書－第75期第2四半期(2019/07/01－2019/09/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed with the Kanto Local Finance Bureau in Japan, as indicated by the header and the regulatory reference to the Financial Instruments and Exchange Act. It contains detailed financial statements, management analysis (MDA), and audit review information for the second quarter of the 75th fiscal period (April 1, 2019, to September 30, 2019). This fits the definition of an Interim/Quarterly Report (IR). H1 2020
2019-11-13 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.